loading page

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Plasma Levels and Thr325Ile Genetic Polymorphism in a Cohort of Egyptian Sickle Cell Disease Patients and Impact on Disease Severity
  • +1
  • Mona Hamdy,
  • Iman Shaheen,
  • Mohamed Khallaf,
  • Yasmeen Selim
Mona Hamdy
Cairo University Kasr Alainy Faculty of Medicine
Author Profile
Iman Shaheen
Cairo University Kasr Alainy Faculty of Medicine
Author Profile
Mohamed Khallaf
Cairo University Kasr Alainy Faculty of Medicine
Author Profile
Yasmeen Selim
Cairo University Kasr Alainy Faculty of Medicine

Corresponding Author:[email protected]

Author Profile


Background: Thrombin is a critical protease modulating thrombosis as well as inflammation which are one of the main pathophysiological mechanisms in sickle vasculopathy, and its levels were reported to be high in sickle cell disease (SCD). The thrombin-thrombomodulin complex activates an inhibitor of fibrinolysis called TAFI acting by reducing plasmin affinity for its substrate hindering fibrinolysis. Objective: We aimed to determine the influence of the Thr325Ile single nucleotide polymorphism on TAFI antigen levels and potential effects on the severity of SCD in a cohort of Egyptian patients. Methods: Genotyping of Thr325lle polymorphism using Taq-Man SNP genotyping assay and TAFI level measurement using an Enzyme-Linked Immunosorbent Assay (ELISA) were performed for 80 SCD patients and 80 health control subjects. Results: Plasma TAFI levels were higher in SCD patients with Thr325Ile polymorphism, yet the difference was not statistically significant (p=0.204). SCD patients with polymorphic genotypes had a greater number of hospital admissions (p=0.03), Ten patients with acute chest syndrome had the homozygous polymorphic genotype (GG), and all patients with pulmonary hypertension had the polymorphic genotype (6 were homozygous [GG] and 5 were heterozygous [GA]). SCD patients complicated with pulmonary hypertension showed significantly higher plasma TAFI levels (p= 0.044). Conclusion: The analysis of Thr325Ile polymorphism combined with plasma TAFI level possibly suggests that the analyzed SNP could influence plasma levels and subsequently disease severity and hospitalization rate, which might be regarded as predictors for complex disease.
08 Nov 2023Submitted to Pediatric Blood & Cancer
08 Nov 2023Assigned to Editor
08 Nov 2023Submission Checks Completed
08 Nov 2023Review(s) Completed, Editorial Evaluation Pending
08 Nov 2023Reviewer(s) Assigned